Title
Category
Credits
Event date
Cost
Recorded Presentation from the NCCN Pharmacy Updates: Novel Therapies for Treating ESR1 and RET-Fusion Mutations in Breast Cancer
  • Breast Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
It is important for clinicians to have an understanding of the current treatment approaches, especially for disease that has progressed and also demonstrated mutations such as ESR1 and RET-fusion.
Archived NCCN Tumor Boards: Treatment Selection Strategies and Barriers to Clinical Care in Metastatic Breast Cancer
  • Breast Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
$0.00
Clinicians need to understand the diverse and evolving SDOH landscape, especially as it relates to clinical trial access for individuals with metastatic breast cancer (mBC), and they need to consider potential strategies to address SDOH to ensure equitable care and improve overall outcomes for patients with mBC.
Biomarker Testing and Interpretation after Breast Cancer Diagnosis
  • Breast Cancer
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
Clinicians can benefit greatly from understanding the technology involved in genomic and molecular testing and profiling assays and their interpretation. Clinicians should know what, when, and how to test and how to make subsequent informed, patient‐personalized treatment decisions. Accurate interpretation of results is critical — over-interpretation or misinterpretation will lead to treatment of patients with ineffective and expensive therapies, negatively impacting patient outcomes.
Neoadjuvant/Adjuvant Treatment of Early-Stage Breast Cancer with SABCS Updates
  • Breast Cancer
  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 ASWB continuing education credit
  • 1.25 Participation
$0.00
The treatment landscape of breast cancer is evolving constantly. The decision-making process of treatment selection should involve careful consideration of the available evidence and a detailed discussion of the associated benefits and risks with patients. Staying up to date with the available treatment options is important to integrate new evidence-based data into clinical practice, and being familiar with their toxicity profile and supportive care information is important to optimize patient outcomes.
Updates to Radiation Therapy for Invasive Breast Cancer with SABCS Updates
  • Breast Cancer
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
The strategies for adjuvant radiation therapy have evolved over the years aiming to de-escalate the therapy in order to balance treatment efficacy with minimized adverse outcomes. Therefore, there is a strong need for education in this area to avoid the potential risk for overtreatment of patients. Using a case-based approach can be beneficial for clinicians to help them understand the de-escalation approaches for omitting radiation—hypofractionation, Partial Breast Irradiation (PBI), and selection of patients with low risk of recurrence.
Surgical Management of DCIS and Invasive Breast Cancer with SABCS Updates
  • Breast Cancer
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
$0.00
There is a growing emphasis on individualizing surgical treatment based on patient and tumor specific factors. Considerable progress has been made in understanding which patients will benefit from surgery and ways to optimize surgical procedures that maximize clinical benefit while minimizing treatment-related adverse effects such as lymphedema. In order to define clinical situations that require specific surgical methods, clinicians need to stay up to date on the updates as well as the controversies.
Management of CNS Metastases in Patients with Breast Cancer
  • Breast Cancer
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
Advances in diagnosis and treatment have increased the survival of patients with advanced breast cancer; however, longevity is associated with an increased detection of brain metastases in these individuals. Important considerations in managing breast cancer that has metastasized to the brain are multifaceted and include molecular subtype, extent and volume of disease, performance status, symptomatic/asymptomatic presentation, and availability of reasonable systemic therapeutic options.
Advances in the Management of Metastatic Breast Cancer with SABCS Updates
  • Breast Cancer
  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 ASWB continuing education credit
  • 1.25 Participation
$0.00
The decision-making process for management of metastatic breast cancer should involve careful consideration of the available evidence for selection of optimal therapy and a detailed discussion with patients of the benefits and risks associated with all possible treatment strategies. With expanding treatment options, clinicians should understand important criteria used in selecting optimal first-and subsequent-line therapies for individuals with metastatic breast cancer.
Inequities in Clinical Outcomes in Breast Cancer: Do Biologic Differences Based on Ancestry/Racial Identity Play a Role?
  • Breast Cancer
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
$0.00
The treatment landscape for breast cancer has shifted dramatically over the last several decades and, despite the increasing incidence of breast cancer, overall survival rates continue to improve. However, data continues to show inequities in cancer prevention/care and survival rates among diverse populations. Although most of this disparity is related to social determinants of health, varying clinicopathologic/genetic/genomic features among those with African ancestry, for example, also play a role.
Survivorship Care for Patients Living with Metastatic Breast Cancer
  • Breast Cancer
  • Survivorship
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 ASWB continuing education credit
  • 1.00 Participation
$0.00
The population of survivors living long-term with incurable breast cancer has grown rapidly, and clinicians may not be aware of how to manage the many unique issues and needs faced by this population. With limited data to guide healthcare providers who work with survivors with metastatic breast cancer, education on the recommendations by experts can help providers create a comprehensive plan to treat the disease while also helping the survivor manage side effects, comorbidities, and psychosocial concerns and maintain long-term health.

Pages